President Andrés Manuel López Obrador (AMLO) reported this Wednesday that the Mexican vaccine “Patria” is already in phase 2 of the investigation.
Investigation in the country is still ongoing
During the morning press conference, the federal president indicated that research continues for the development of this ANTICOVID vaccine that will be manufactured in the country.
Progress is being made in the investigation of the Patria vaccine that will be produced in Mexico, it is already moving to a second phase in the research process. There are good results in the first stage of the investigation process. AMLO.
For the advances of the “Patria” vaccine in which 150 million pesos had been invested
Last April, the general director of the National Council of Science and Technology (Conacyt), María Elena Álvarez-Buylla Roces. He presented the advances of the “Patria” vaccine in which 150 million pesos had been invested: 135 million pesos from Conacyt and 15 million pesos from the alliance established with the Mexican Agency for International Development Cooperation (Amexcid) and the Ministry of Foreign Relations (SRE).
30% of the doses would go to countries that have not had access to biological
According to the Mexican government’s schedule, production of the vaccine is expected before the end of the year and if successful. 30% of the doses would go to countries that have not had access to the biological.
López Obrador also indicated that the country’s health authorities are analyzing whether to apply a booster of the vaccine for vulnerable sectors in 2022. Although he stressed, “specialists say that a booster vaccine is not necessary.”
The president insisted that his government maintains the commitment that all people over 18 years of age will be vaccinated this October.
Development phases of COVID-19 vaccines
The development phases of the assets against COVID-19 they refer to the testing stages that an experimental vaccine goes through.
Like all drugs, each vaccine must pass extensive and rigorous testing. Which guarantee its safety before introducing it into a national vaccination program.
Above all, each vaccine in development must undergo research and evaluation to identify the antigens that should be used to generate an immune response. This preclinical phase is done without testing in humans. An experimental vaccine is initially tested in animals, in order to assess its safety and its chances of preventing disease.
If the vaccine elicits an immune response, it is tested in human clinical trials, in three phases, according to the World Health Organization.
PHASES
In the Phase 1, the vaccine is administered to a small number of volunteers in order to assess its safety, confirm that it elicits an immune response, and determine the correct dose.
In this phase, vaccines are generally tested in healthy young adult volunteers.
On the other hand, the Phase 2, the vaccine is administered to several hundred volunteers, in order to further evaluate its safety and its ability to elicit an immune response. In this phase, multiple trials are usually carried out to evaluate different age groups and different vaccine formulations.
Generally, this phase includes a group that is not vaccinated, with a view to making comparisons and determining whether changes in the vaccinated group are attributable to the vaccine or have occurred by chance.
Later, in the Phase 3, the vaccine is given to thousands of volunteers, and comparisons are made with a similar group of people. Which were not vaccinated but received a comparator product.
In order to determine if the vaccine is effective against the disease and to study its safety in a much larger group of people.
Phase 3 trials are typically conducted in many countries and at numerous locations within each country. In order to ensure that the conclusions regarding the efficacy of the vaccine are valid in relation to many different populations.
Related Notes:
Prolonged COVID increases when the virus disrupts red and white blood cells
Variant R.1 COVID: Why should we be vigilant?
WHO Endorses Regeneron’s Antibody Cocktail for COVID; ask to lower your price